Reduced-intensity regimens: multivariate analysis of outcomes
| Outcome . | No. of events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Grades 2 to 4 acute GVHD* | |||
| Haplo | 389/1171 | 1.00 | |
| MUD | 49/180 | 0.70 (0.52-0.95) | .022 |
| Grades 3 and 4 acute GVHD† | |||
| Haplo | 118/1167 | 1.00 | |
| MUD | 8/179 | 0.41 (0.20-0.85) | .016 |
| Chronic GVHD‡ | |||
| Haplo | 309/1195 | 1.00 | |
| MUD | 51/185 | 0.80 (0.60-1.09) | .15 |
| Relapse§ | |||
| Haplo | 512/1205 | 1.00 | |
| MUD | 72/187 | 0.99 (0.75-1.31) | .94 |
| Nonrelapse mortality║ | |||
| Haplo | 205/1205 | 1.00 | |
| MUD | 18/187 | 0.33 (0.19-0.57) | <.0001 |
| Disease-free survival¶ | |||
| Haplo | 717/1205 | 1.00 | |
| MUD | 90/187 | 0.74 (0.60-0.93) | .008 |
| Overall survival# | |||
| Haplo | 568/1211 | 1.00 | |
| MUD | 65/187 | 0.65 (0.50-0.84) | .001 |
| Outcome . | No. of events/evaluable . | HR (95% CI) . | P . |
|---|---|---|---|
| Grades 2 to 4 acute GVHD* | |||
| Haplo | 389/1171 | 1.00 | |
| MUD | 49/180 | 0.70 (0.52-0.95) | .022 |
| Grades 3 and 4 acute GVHD† | |||
| Haplo | 118/1167 | 1.00 | |
| MUD | 8/179 | 0.41 (0.20-0.85) | .016 |
| Chronic GVHD‡ | |||
| Haplo | 309/1195 | 1.00 | |
| MUD | 51/185 | 0.80 (0.60-1.09) | .15 |
| Relapse§ | |||
| Haplo | 512/1205 | 1.00 | |
| MUD | 72/187 | 0.99 (0.75-1.31) | .94 |
| Nonrelapse mortality║ | |||
| Haplo | 205/1205 | 1.00 | |
| MUD | 18/187 | 0.33 (0.19-0.57) | <.0001 |
| Disease-free survival¶ | |||
| Haplo | 717/1205 | 1.00 | |
| MUD | 90/187 | 0.74 (0.60-0.93) | .008 |
| Overall survival# | |||
| Haplo | 568/1211 | 1.00 | |
| MUD | 65/187 | 0.65 (0.50-0.84) | .001 |
Model adjusted for graft type (peripheral blood: HR, 1.34; 95% CI, 1.10-1.64; P = .004).
Model not adjusted; no significant factors.
Model adjusted for graft type (peripheral blood: HR, 2.14; 95% CI, 1.76-2.59; P < .0001) and conditioning regimen (non-TBI: HR, 0.67; 95% CI, 0.49-0.92; P = .015).
Model adjusted for disease risk index (high-risk: HR, 2.11; 95% CI, 1.74-2.56; P < .0001).
Model adjusted for age (>55 y: HR, 1.62; 95% CI, 1.17-2.24; P = .004), hematopoietic comorbidity index (≥3: HR, 1.70; 95% CI, 1.29-2.23; P = .0002), graft type (peripheral blood: HR, 1.39; 95% CI, 1.05-1.85; P = .02), and conditioning regimen (non-TBI: HR, 1.68; 95% CI, 1.11-2.55; P = .014).
Model adjusted for hematopoietic comorbidity index (≥3: HR, 1.26; 95% CI, 1.09-1.45; P = .001) and disease risk index (high-risk: HR, 2.16; 95% CI, 1.83-2.54; P < .0001).
Model adjusted for age (>55 y: HR, 1.43; 95% CI, 1.19-1.72; P = .0001), hematopoietic comorbidity index (≥ 3: HR, 1.32; 95% CI, 1.12-1.54; P = .0007), and disease risk index (high-risk: HR, 2.16; 95% CI, 1.81-2.59; P < .0001).